

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 November 2004 (04.11.2004)

PCT

(10) International Publication Number  
**WO 2004/094664 A1**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68

(21) International Application Number:  
PCT/GB2004/001673

(22) International Filing Date: 16 April 2004 (16.04.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0308851.5 16 April 2003 (16.04.2003) GB

(71) Applicant (for all designated States except US): LINGVITAE AS [NO/NO]; Trimveien 6, A562, N-0372 Oslo (NO).

(71) Applicant (for AG only): JAPPY, John, William, Graham [GB/GB]; Gill Jennings & Every, Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LEXOW, Preben

[NO/NO]; LingVitae AS, Trimveien 6, A562, N-0372 Oslo (NO). RAGNHIL DSTVEIT, Erlend [NO/NO]; LingVitae AS, Trimveien 6, A562, N-0372 Oslo (NO).


(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: METHOD FOR CHARACTERISING POLYNUCLEOTIDES



(57) Abstract: The method of the invention is used to identify specific characteristics of a target polynucleotide in a sample, and comprises the steps of: i) attaching to one end of each target polynucleotide in the sample a polynucleotide signal sequence that is specific for the characteristic under study; ii) contacting the target polynucleotides with a molecule that interacts with the target polynucleotide if the characteristic is present; iii) attaching a polynucleotide adapter sequence to those targets polynucleotides that interact with the molecule of step (ii), the adapter being attached at the end of the target polynucleotide opposite that at which the signal sequence is attached; iv) carrying out a polynucleotide amplification reaction on those target polynucleotides that comprise both the adapter and signal sequence, optionally repeating steps (i) to (iv) for other characteristics; and (v) identifying which signal sequences are present on the amplified products, and in which order, to thereby determine the characteristics of each target polynucleotide.

WO 2004/094664 A1



Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), Euro-  
pean (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

— before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

JC20 Rec'd PCT/PTO 14 OCT 2008

## METHOD FOR CHARACTERISING POLYNUCLEOTIDES

Field of the Invention

This invention relates to methods for converting a target polynucleotide into readable information chains, for subsequent determination of the sequence of the target polynucleotide.

Background to the Invention

Advances in the study of molecules have been led, in part, by improvement in technologies used to characterise the molecules or their biological reactions. In particular, the study of the nucleic acids DNA and RNA has benefited from developing technologies used for sequence analysis and the study of hybridisation events.

The principal method in general use for large-scale DNA sequencing is the chain termination method. This method was first developed by Sanger and Coulson (Sanger *et al.*, Proc. Natl. Acad. Sci. USA, 1977; 74: 5463-5467), and relies on the use of dideoxy derivatives of the four nucleotides which are incorporated into the nascent polynucleotide chain in a polymerase reaction. Upon incorporation, the dideoxy derivatives terminate the polymerase reaction and the products are then separated by gel electrophoresis and analysed to reveal the position at which the particular dideoxy derivative was incorporated into the chain.

Although this method is widely used and produces reliable results, it is recognised that it is slow, labour-intensive and expensive.

US-A-5302509 discloses a method to sequence a polynucleotide immobilised on a solid support. The method relies on the incorporation of 3-blocked bases A, G, C and T having a different fluorescent label to the immobilised polynucleotide, in the presence of DNA polymerase. The polymerase incorporates a base complementary to the target polynucleotide, but is prevented from further addition by the 3'-blocking group. The label of the incorporated base can then be determined and the blocking group removed by chemical cleavage to allow further polymerisation to occur. However, the need to remove the blocking groups in this manner is time-consuming and must be performed with high efficiency.

WO-A-00/39333 describes a method for sequencing polynucleotide by converting the sequence of a target polynucleotide into a second polynucleotide having a defined sequence and positional information contained therein. The sequence information of the target is said to be "magnified" in the second polynucleotide, allowing greater ease of distinguishing between the individual bases on the target molecule. This is achieved using "magnifying tags" which are predetermined nucleic acid sequences. Each of the bases adenine, cytosine, guanine and thymine on the target molecule is represented by an individual magnifying tag, converting the original target sequence into a magnified sequence. Conventional techniques may then be used to determine the order of the magnifying tags, and thereby determining the specific sequence on the target polynucleotide.

In a preferred sequencing method, each magnifying tag comprises a label, e.g. a fluorescent label, which may then be identified and used to characterise the magnifying tag.

Although the method disclosed in this patent publication has many advantages, there is still a need for improved methods for sequencing target polynucleotides.

#### Summary of the Invention

According to a first aspect of the present invention, a method for identifying specific characteristics of a target polynucleotide present in a sample, comprises the steps of:

- i) attaching to one end of each target polynucleotide in the sample a polynucleotide signal sequence that is specific for the characteristic under study;
- ii) contacting the target polynucleotides with a molecule that interacts with the target polynucleotide if the characteristic is present;
- iii) separating those target polynucleotides that interact from those that do not;
- iv) optionally repeating steps (i) to (iii); and

- (v) identifying which signal sequences are present on the separated target polynucleotides, and in which order, to thereby determine the characteristics of each target polynucleotide.

The method of the present invention permits multiple characteristics of a target polynucleotide to be determined in a simple manner that can be readily automated. In the preferred embodiment, the method relies on the incorporation of two polynucleotides molecules onto those targets having the specific characteristic, allowing an amplification reaction to be performed, to thereby selectively increase the number of target polynucleotides with the desired characteristic and to effectively remove those targets lacking the characteristic. The method is particularly suitable for determining the sequence of a target polynucleotide.

According to a second aspect of the invention, a method for determining the sequence of a target polynucleotide, comprises the steps of:

- i) treating a sample of a double-stranded target polynucleotide to create overhangs at the 5' and 3' ends, each with a defined number of bases;
- ii) dividing the sample and contacting each separate sample with a double-stranded polynucleotide signal sequence and a double-stranded adapter polynucleotide, each signal sequence representing a specific polynucleotide sequence at the 5'-overhang, and comprising an overhang that permits hybridisation and ligation to the 3' end of the target polynucleotide, and each adapter comprising an overhang that is of complementary sequence to that of the sequence represented by the signal sequence;
- iii) carrying out the polymerase reaction on the sample(s) using primers that hybridise to the signal sequence and adapter sequence, wherein the product of the polymerase reaction comprises a restriction site that permits cleavage of the adapter and that part of the target polynucleotide that formed the 5'-

- overhang, to form a new 5'-overhang, optionally repeating steps (i) to (iii) using restriction enzymes to create the overhangs; and
- iv) identifying which signal sequences are present on the amplified products, and in which order, to thereby determine the sequence of the target polynucleotide.

#### Description of the Drawings

The invention is described with reference to the accompanying figures, wherein:

Figure 1 is a schematic representation of a signal sequence, illustrating the conversion of part of a target polynucleotide into a defined signal sequence;

Figure 2 is a schematic representation of a polynucleotide sequencing experiment carried out using the present invention;

Figure 3 is a schematic representation of the use of different compartments with associated specific signal sequences in a conversion process;

Figure 4 shows the results of conversion, with three cycles being performed to form a series of signal sequences representing the base sequence on a target polynucleotide;

Figure 5 is a schematic representation of a polynucleotide sequencing experiment, carried out to determine a three base sequence per cycle; and

Figure 6 shows the results of conversion, demonstrating the incorporation of specific signal sequences onto a target polynucleotide.

#### Description of the Invention

The method of the present invention is an adaptation of the conversion method disclosed in WO-A-00/39333. In summary, the present invention permits specific characteristics of a target polynucleotide to be identified based on the incorporation of specific signal sequences. The signal sequences are incorporated onto all the target polynucleotides present in a sample, but only those that comprise the specific characteristic are separated and characterised.

The method is particularly suitable for determining the sequence of a target polynucleotide. Using the method, a defined number of sequences at one

end of the target polynucleotide can be converted into a defined signal sequence at the other end of the target polynucleotide. Through a series of steps, the "sequenced" end of the target is cleaved, while the signal sequence end is built up, generating a defined series of signal sequences which can be determined  
5 through a subsequent identification step.

The term "polynucleotide" is well known in the art and is used to refer to a series of linked nucleic acid molecules, e.g. DNA or RNA. Nucleic acid mimics, e.g. PNA, LNA (locked nucleic acid) and 2'-O-methRNA are also within the scope of the invention.

10 The reference herein to the bases A, T(U), G and C, relate to the nucleotide bases adenine, thymine (uracil), guanine and cytosine, as will be appreciated in the art. Uracil replaces thymine when the polynucleotide is RNA, or it can be introduced into DNA using dUTP, again as well understood in the art.

Reference is made herein to the 5' and 3' ends of the target  
15 polynucleotide. In certain embodiments the target polynucleotide is double-stranded, and so each end comprises both 5' and 3' ends. However, the reference to 5' and 3' ends is made with reference to the strand of the target that is under study or is being sequenced. It will also be apparent that where the specification refers to the 5' end as the end being sequenced, it will be possible  
20 to modify the procedure so that it is the 3' end that is sequenced, i.e. the signal sequences and adapters ligate to opposite ends to those indicated herein.

In its broadest aspect, the invention allows the identification of specific characteristics of the target polynucleotide. A characteristic may be the sequence of the polynucleotide. Alternatively, a characteristic may be the ability  
25 of the target polynucleotide to bind to other molecules, for example to DNA-binding proteins or to hybridise to complementary polynucleotides. The method may also be used to identify and characterise restriction enzyme sites present within the target polynucleotide sequence.

Each characteristic is identified by carrying out a reaction with a molecule  
30 that interacts with a target polynucleotide having the characteristic and discriminates from those lacking the characteristics. Those target polynucleotides that interact with the molecule are labelled with a signal

sequence that is specific for the characteristic and permits the characteristic to be determined in a later read-out step.

The present invention relies on the incorporation of a signal sequence on to all target polynucleotides in a sample, with the signal sequence representing  
5 a specific characteristic under study. The target polynucleotides are then contacted with a molecule and those that interact are separated. In this way, it is possible to identify the characteristic on identification of the signal sequence.

The separation of those target molecules that interact with the molecule can be carried out in various ways. For example, the molecule may contain a  
10 binding moiety that permits separation of the target polynucleotide/molecule complex. Suitable binding moieties include antibodies and biotin/streptavidin. Alternatively, size separation may be carried out, as it will be possible to distinguish the target/molecule complex from non-complexed components.

The preferred embodiment of the present invention relies on the  
15 incorporation of a polynucleotide signal sequence and polynucleotide adapter sequence onto the target polynucleotide, which permits an amplification reaction to be carried out to amplify those target polynucleotides which have reacted with a specific molecule. The resulting products of the polymerase reaction may be further characterised by repeating the steps of reacting the target with a  
20 molecule and incorporating a further signal sequence representing the characteristic under study.

The method of the invention is preferably carried out using multiple reaction compartments, one for each putative characteristic being studied. Each reaction compartment has an associated signal sequence specific for that  
25 compartment. The sample containing the target polynucleotides is divided between the reaction compartments and a signal sequence is attached, for example by ligation, to one end of each target polynucleotide. The signal sequence is attached to all of the target polynucleotides in the compartment, irrespective of whether the target has the specified characteristic. The next step  
30 is to test for the characteristic by reacting each target with a molecule that interacts specifically with those targets that comprise the characteristic. The



molecule may therefore be a polynucleotide-binding protein, enzyme or other polynucleotide. Those targets that interact with the molecules are then separated. In the preferred embodiment, of the molecule comprises an adapter sequence. Therefore, on interaction between the target and the molecule, the molecule (comprising the adapter) is attached or ligated to the target. Those targets that comprise both a signal sequence and adapter are then amplified.

The amplification reaction may be carried out using any suitable method. The preferred method is to use a conventional polymerase reaction using conditions known in the art. It will be appreciated that other amplification reactions can also be carried out, including isothermal pcr and amplification in bacteria.

A preferred embodiment is to use the method to sequence the target polynucleotide. This is carried out by identifying a defined number of bases, e.g. three or four bases, at one end of the target polynucleotide, and then converting this information into a signal sequence on the opposite end, thereby permitting additional conversion cycles to take place, without the removal of incorporated signal sequences from previous cycles.

The sequencing method may be carried out by obtaining the target polynucleotide and treating this with a series of restriction enzymes to form defined overhang regions at each end of the target polynucleotide, which allow incorporation of a signal sequence and an adapter during each conversion step.

A "signal sequence" is a single-stranded or double-stranded polynucleotide that comprises distinct "units" of nucleic acid sequence. Each characteristic, eg., each of the bases A, T(U), G and C on the target is represented by a distinct and predefined unit, or unique combination of units. Each unit will preferably comprise two or more nucleotide bases, preferably from 2 to 50 bases, more preferably 2 to 20 bases and most preferably 4 to 10 bases, e.g. 6 bases. There are at least two different bases contained in each unit. In a preferred embodiment, there are three different bases in each unit. The design of the units is such that it will be possible to distinguish the different units during a "read-out" step, e.g. involving either the incorporation of detectably labelled nucleotides in a polymerisation reaction, or on hybridisation of complementary

oligonucleotides. For example, if the characteristic being studied is the sequence of the target each base on the target is represented by a specific series of bases in a unit.

In a preferred embodiment, each signal sequence comprises two units of  
5 distinct sequence which represent all of the four bases on the target. According to this embodiment, the two units can be used as a binary system, with one unit representing "0" and the other representing "1". Each base on the target is characterised by a combination of the two units. For example, adenine may be represented by "0" + "0", cytosine by "0" + "1", guanine by "1" + "0" and thymine  
10 by "1" + "1", as shown in Figure 1. It is necessary to distinguish between the units, and so a "stop" signal can be incorporated into each unit. It is also preferable to use different units representing "1" and "0", depending on whether the base on the target (template) polynucleotide is in an odd or even numbered position.

15 This is demonstrated as follows:

Odd numbered template sequence:

"0" : ATTTTAT(CC)

"1" : GTTTTGT(CC)

Even numbered template sequence:

20 "0" : ACCCCCAC(TT)

"1" : GCCCCCGC(TT)

Suitable signal sequences are also described in WO-A-00/39333.

The "adapter" is a single-stranded or double-stranded polynucleotide. The purpose of the adapter is to provide the necessary sequence to permit  
25 amplification to occur. In a preferred embodiment, the adapter is a double-stranded polynucleotide that comprises a defined overhang that is capable of hybridising and ligating to a complementary region on the target polynucleotide. The complementary region is usually at the end of the target opposite that to which the signal sequence incorporates. The adapter provides the necessary  
30 primer binding site necessary in the amplification reaction. In a preferred embodiment, the adapter is designed to hybridise to that part of the target polynucleotide that is being sequenced, i.e. the 5'-overhang part of the target

polynucleotide. If the 5'-overhang on the target is 4 bases, then the complementary overhang on the adapter will also be 4 bases. This permits ligation to occur to form a double-stranded polynucleotide. Given that the 5'-overhang of the target is of unknown sequence, it will usually be necessary to  
5 use a combination of adaptors having all permutations of the (for example) 4 base sequence. The adapters of different sequence will be used in separate reactions, as discussed below.

Each adapter will usually have a restriction enzyme recognition site incorporated, allowing its cleavage during a later step. This can be used to  
10 create a new 5'-overhang.

The sequencing method of the preferred embodiment comprises the following general steps:

#### Digestion

A sample of the target polynucleotide is first treated with one or more  
15 restriction enzymes, resulting in an overhang in the target with a defined number of bases, e.g. 3 bases, that is used for ligation of signal sequences later in the procedure (the overhang). An overhang is also created at the opposite end of the target polynucleotide (the 5'-overhang). It is this overhang that is to be identified (represented) by the signal sequence during the conversion process  
20 and is to be ligated to the adapter.

#### Ligation

The sample with the target polynucleotide is divided evenly into reaction compartments representing all permutations of the overhang to be sequenced. For example, if the overhang to be sequenced is 4 bases, then 256 reaction  
25 compartments are to be used. In the first compartment, the target polynucleotide is contacted with a signal sequence that represents for example AAAA (when the overhang to be sequenced is 4 bases), the signal sequence being ligated to the 3'-overhang on all the target polynucleotides. An adapter polynucleotide with the overhang TTTT is also added, but this will only ligate specifically to the target  
30 polynucleotides which contain an AAAA overhang, leaving polynucleotides with a different overhang sequence with an unligated overhang. The same procedure is performed in the other compartments, each representing a different

combination of the possible 4 base sequence. In each case the adapter will be the complement of the sequence represented by the signal sequence.

Although it is preferable for the signal sequence to represent all of the bases of the overhang, it is possible to sequence fewer bases than those present in the overhang. For example, if the overhang comprises 4 bases, the signal sequence may be used to represent 3 of these. This is illustrated in the Examples disclosed below.

#### Amplification

After the ligation steps have been carried out, the samples can be pooled, and a polymerase reaction carried out. The polymerase reaction is carried out using primers which target the ends of the signal sequence and adapter, and therefore only those molecules that have successfully ligated both the signal sequence and the adapter sequence will be amplified exponentially, while those molecules containing only a signal sequence will be removed as a consequence of linear amplification. The result will be a population of converted polynucleotide fragments, where the 4 base overhang that was initially generated at one end of the target polynucleotide has been replaced with a signal sequence representing the 4 bases at the other end of the target polynucleotide.

In a preferred embodiment, the polymerase reaction is carried out using methyl-dCTP, which ensures that native restriction enzyme sites remain inactive. Additional restriction enzyme sites are incorporated by the adapter molecules, thereby permitting further conversion cycles to occur. The primers used in the polymerase reaction are specific for sequences found within the signal sequence and adapter, thereby ensuring that the amplification step occurs only when both the signal sequence and adapter is ligated onto the target polynucleotide.

It is also preferable for the primer binding sites to be different in the different sets of signal sequence and adapter, ie., the signal sequence and adapter used in one conversion cycle will comprise different primer binding sites from those used in an earlier cycle. This ensures that the correct sequence is amplified.

The overhangs may be produced by different means, although the preferred embodiment is to use restriction enzymes, e.g. class IIs restriction enzymes. These enzymes exhibit no specificity to the sequence that is cut and they can therefore generate overhangs with all types of base compositions. The binding site of the restriction enzyme can be located so that an overhang is formed inside the actual target polynucleotide. In practice, it is preferable to choose enzymes that generate 3-4 base pair overhangs.

Class IIs restriction endonucleases are known, and are identified in WO-A-00/39333.

In one embodiment, the target polynucleotide is first treated with an adapter polynucleotide which incorporates a recognition sequence for the restriction enzyme BbvI, and the polynucleotide is then treated with the restriction enzyme to generate a specific overhang at the 5' end. Native recognition sites for BbvI are inactivated by first treating the target polynucleotide by methylation. Having created the first overhang, subsequent overhangs at the 5' end are preferably created using the restriction enzyme SfaNI. This is carried out by ligating a specific adapter sequence at the 5' end which incorporates the recognition sequence for SfaNI.

The initial overhang at the 3' end is preferably created by ligating a polynucleotide that incorporates a defined overhang. The defined overhang permits a first signal sequence to hybridise and ligate at the 3' end. In another embodiment, the target polynucleotide is first treated with an adapter polynucleotide which incorporates a recognition sequence for the restriction enzymes MmeI and EarI (or its isoschizomer Eam 1104I). The polynucleotide is then treated with the restriction enzyme MmeI to cleave off 20 basepairs from the target molecule and associate it with the adapter polynucleotide. A second adapter polynucleotide, containing a recognition sequence for the restriction enzyme SfaNI, is then ligated to the adapter-associated target polynucleotide via the MmeI generated overhang. A PCR amplification is carried out to amplify the fragments containing the 20 bp target polynucleotide flanked by two adapter polynucleotides. To protect internal sites from subsequent EarI and SfaNI digestion, the PCR is carried out with methylated dCTP replacing normal dCTP

in the dNTP mix. Amplification of target polynucleotides flanked by Mmel generated overhangs (i.e., by-products from the digestion), can be eliminated by using unphosphorylated second adapters. The specific overhang at the 5' end is created by digesting the PCR product with the restriction enzyme SfaNI (or equivalents). The defined overhang at the 3' end is created by digesting the PCR product with the restriction enzyme Earl (or Eam1104I). The signal sequence incorporates a restriction enzyme site, which is preferably for the restriction enzyme Earl. Subsequent cycles of cleavage and incorporation occur using the restriction enzymes Earl and SfaNI, as shown in Figure 2.

The conversion cycle is further illustrated in Figure 3, which shows the fate of five different fragments within three arbitrarily picked reaction compartments out of the 256 compartments used in the procedure. The fragments are first evenly distributed into the 256 compartments. In compartment 56, where the overhang "TCTA" is to be identified, a signal sequence representing this base composition is introduced and ligated with the 3 base 3'-overhang on the left end of the target polynucleotide. This ligation occurs regardless of the composition of the 4 base 5'-overhang on the right side of the polynucleotide. A specific adapter, that only ligates with fragments with 3' TCTA -5' overhangs, is then introduced and ligated. Mismatch ligation of the adapter can be reduced by performing the ligation in presence of "blocking" adapters. Blocking adapters have a different overhang sequence than the specific adapter and hence ligate to target polynucleotides having a non-complementary overhang to the specific adapter. A final amplification reaction then selectively amplifies the fragments that have ligated with the specific adapter and hence removes the other fragments which have been associated with an incorrect signal sequence. The same procedure is performed in compartments 141 and 194 with the exception that the composition of the signal sequences and the adapters are adjusted in accordance with the overhangs that are to be identified in the wells (3'-ATAG-5' and 3'-CAAT-5').

The target polynucleotides from the 256 compartments are preferably pooled into one common reaction tube before the amplification reaction takes

place, thereby avoiding the inconvenience of performing 256 separate amplification reactions.

After subsequent conversion cycles are carried out, the sequence at the 5' end of the target polynucleotide is reduced and the signal sequences introduced at the 3' end of the target polynucleotide are increased in a defined way corresponding to the now "sequenced" target polynucleotide. Determining the type and order of the signal sequences may be carried out using methods disclosed in WO-A-00/39333, or in the co-pending International Patent Application filed in the name of LingVitae and claiming priority from GB0308852.3.

The amplification reaction may produce unwanted artefacts and various steps can be taken to reduce or remove these. For example, it is preferable if the primer recognition site on different signal sequences (and optionally also different adapters) is different, to reduce the likelihood of primers binding to internal signal sequences and amplifying fragments of the larger converted target.

It is also preferable to design the signal sequences so that consecutive or subsequent signal sequences comprise distinct base sequences. This ensures that primers introduced to hybridise to the terminal signal sequence, do not hybridise to internal signal sequences, resulting in fragments being produced during the amplification step.

Incomplete digestion by one or more of the restriction enzymes may also be a source of artefacts. Utilising restriction enzymes having high specificity and activity will reduce this problem.

Artefacts may also be removed by gel purification, or by immobilising the products prior to digestion with the restriction enzyme; those products not completely digested will remain immobilised and can be separated from those products that have undergone complete digestion.

The removal of excess adapters and targets prior to amplification will also reduce the production of artefacts.

The following Examples illustrate the invention.

#### Example 1

**Initial preparation using BbvI and no size restriction**

Prior to (or after) DNA fragmentation the target polynucleotide is methylated to inactivate native recognition sites. Using BbvI as the restriction enzyme, M.Bbv (Megabase Research Products) is used to inactivate its native sites. The target polynucleotide is randomly fragmented into pieces of 500-1000 base pairs by mechanical shearing using a HydroShear device (GeneMachines). In combination with sonication, even shorter fragments can be generated. To increase the efficiency of the subsequent step of blunt-end adapter ligation, the sheared polynucleotides are optionally treated with DNA polymerase to fill in or remove overhangs using its exonuclease function. T4 DNA polymerase and Klenow Large fragment alone or in combination are commonly used for this purpose.

Two sorts of polynucleotide adapters are blunt-end ligated to the target polynucleotide fragments. One incorporates a BbvI site and the other incorporates an overhang for subsequent ligation to a signal sequence. Each adapter has a length of 10-20 base pairs and is added in a 10X molar excess to the target polynucleotides. The adapters are phosphorylated except for one of the strands of the BbvI adapter. In addition, the opposite strand of this adapter carries a 3' deoxy group to prevent concatemerization during ligation. The ligation is performed under optimized conditions for blunt-end ligation following manufacturers recommendations.

The ligated polynucleotide fragments are digested with BbvI. After digestion, a size selection (e.g., gel separation or column fractionation) is performed to remove excess adapters, cleaved end fragments and polynucleotide fragments below and above a certain threshold value (e.g., two-fold size distribution).

**Example 2.****Initial preparation using MmeI and size restriction**

The target polynucleotide is randomly broken into pieces of 500-1000 base pairs by mechanical shearing using a HydroShear device (GeneMachines). Together with sonication, shorter fragments can be generated. To increase the efficiency of the subsequent step of blunt-end



adapter ligation, the sheared polynucleotides are optionally treated with DNA polymerase to fill in or remove overhangs as discussed in Example 1.

A 10X molar excess of a 20-40 bp blunt-end adapter is ligated to the fragmented target polynucleotides. The ligation is performed under optimized  
5 conditions for blunt-end ligation following the manufacturer's recommendations. Only the anti-sense strand of the adapter is phosphorylated to ensure unidirectional ligation (in addition the anti-sense strand incorporates a 3' dideoxy group or blocking group to prevent concatemerization). The adapter carries at its very 3' end a restriction site for MmeI and a restriction  
10 site for EarI (or Eam1104I) further upstream. Size exclusion or affinity spin columns (e.g., MinElute PCR clean-up from Qiagen) are conveniently used to remove excess adapters as well as changing buffer.

MmeI digestion is performed under optimal conditions to cleave 20 basepairs from the target molecule and associate it with the adapter  
15 polynucleotide. A spin column is used to change buffer (e.g. BioSpin-6 from BioRad). A second adapter polynucleotide, containing a recognition sequence for the restriction enzyme SfaNI, is then ligated to the adapter-associated target polynucleotide via the MmeI generated overhang (because MmeI generates a two bases 3' overhang, the second adapter is a pool of adapters  
20 having all the 16 permutations of two bases in the 3' overhang). The SfaNI site is positioned to cut into the terminal four bases of the target sequence. The adapter is kept unphosphorylated to eliminate subsequent amplification of target polynucleotides containing two MmeI generated overhangs (a by-product from the target polynucleotide digestion). A PCR amplification is  
25 carried out to amplify the fragments containing the 20 bp target polynucleotide flanked by two adapter polynucleotides. To protect internal sites from subsequent EarI and SfaNI digestion, the PCR is carried out with methylated dCTP replacing normal dCTP in the dNTP mix.

A PCR clean-up spin column is used to remove excess primers, DNA  
30 polymerase and to change buffer.

The PCR amplified material is digested with EarI (or Eam1104I) and SfaNI to generate the overhangs needed for signal sequence ligation and for

biochemical conversion. By using biotinylated primers in the PCR, digested end fragments can be removed by means of affinity (e.g., streptavidin coated beads).

Example 3.

5       **The principle of cyclic conversion where four nucleotides are converted per cycle**

The principle of cyclic conversion of nucleic acid bases into readable signal sequences was demonstrated by converting a sequence of 12 bases in a target DNA into its corresponding signal chain. The conversion took place  
10 in steps through a cyclic method, where 4 bases were converted in each cycle for a total number of 3 cycles. The end product was a signal chain consisting of 12 signal components representing the relevant base sequence in the target DNA. The experiment is described schematically in Figure 2.

A target DNA fragment of 240 bp, containing internal sites for *Sfa*NI and  
15 *Eam*1104I was PCR-amplified from the bacteriophage Lambda genome (1507-1703) using primers containing restriction sites for *Eam*1104I and *Sfa*NI (the top fragment in Figure 2) respectively. In order to avoid cutting from the internal sites later, the PCR reaction was conducted with methylated deoxy-Cytosine nucleotides (m5-dCTP) instead of the usual deoxy-Cytosine (dCTP).  
20 PCR conditions: (50 µl): 10 mM KCl, 10mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 20mM Tris-HCl, 0.1% Triton-X-100, pH 8.8 (Thermopol buffer, New England Biolabs), 2 mM Mg<sup>2+</sup>, 200 µM dNTP (- dCTP) and 200 µM m5-dCTP (Amersham Pharmacia Biotech), 20 pmol Lambda primer #328 (5'-  
agactggcgatccctggcatcaccctccagcgtgttttat-3'; SEQ ID No 1) and 20 mpol  
25 Lambda primer #329 (5'-gcactgataggcgtcactcttcgctgtacgtglccagatgt-3'; SEQ ID No 2) (MWG biotech), 10 ng Lambda genome, 1U Vent polymerase (New England Biolabs). The PCR cycling was conducted with a PTC-200 (MJResearch). Hot start: 95°C, 5 minutes, 35 cycles consisting of: 95°C, 15 seconds, 58°C, 20 seconds, 72°C, 30 seconds. Complete extension step:  
30 72°C, 5 minutes.

Cycle 1:

The fragment enters the sequencing cycle (Figure 2, A) and is cut with

*Eam*1104I and *Sfa*NI (as the internal sites are methylated and protected against cutting, cutting will only take place from the primer areas). Digestion conditions: 100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl<sub>2</sub>, 1 mM DTT, pH 7.9 (NEB3, New England Biolabs), 1 µg methylated PCR fragment, 20 U

5 *Eam*1104I, 3U *Sfa*NI, and incubation for one hour at 37°C. The enzymes were heat-inactivated at 65°C for 20 minutes. The cut fragment was cleaned using GibcoBRL PCR purification system (Gibco) and then eluted with 10 mM Tris-HCl. The cut fragment corresponds to the nature of those fragments that are obtained after an initial preparation or one cycle of conversion (described in

10 Example 1) in that it has an overhang of 3 bases for signal chain ligation and an overhang of 4 bases for ligation to a specific right hand adapter.

The conversion step where the selection marker is attached (Figure 2, B) was carried out by ligating the fragment with the specific adapter and its associated signal sequence: 40 mM Tris-HCl, 10 mM MgCl<sub>2</sub>, 10 mM DTT, 0.5

15 mM ATP, pH 7.8 (Ligase buffer, Fermentas), 1.6 pmol adapter1 (5'-Biotin-ggctaggctgctgatgaacgcacg-3; SEQ ID No 3' annealed to 5'-tggacgatgcgttcacgacacctagcc-3'; SEQ ID No 4 (MWG-biotech), 1.9 pmol signal sequence 1 (1), 7.5 Weiss-U T4 DNA ligase (Fermentas). The incubation took place at room temperature (22°C) for 2.5 hours. The ligase

20 was heat-inactivated at 65°C for 10 minutes.

The signal sequences used in the experiment were made in the following way: Signal components (each representing one base) were made by annealing oligonucleotides (approx. 45 bases) which were ligated together to create the desired signal sequences (the signal components are

25 constructed with different overhangs which dictate the sequence of ligation). The signal sequences were amplified by PCR and cut with *Sap*I in order to generate the complementary overhang necessary for ligation of the signal sequence to the target DNA. Since all target DNA fragments have the same overhang for signal sequence ligation, all fragments in a given reaction will be

30 ligated to the same signal sequence, irrespective of the sequence of the *Sfa*NI-generated overhang. Specificity and selection are therefore located in the adapter. As this ligates to that terminus of the target DNA which was cut

with *Sfa*NI, only fragments with complementary overhang to the adapter will be ligated. A conversion therefore presupposes that the target DNA, as well as being ligated to a signal sequence, also has an overhang complementary to the adapter in order for ligation to this to take place. In other words, the adapter ensures a specific selection of fragments with an overhang sequence corresponding to the ligated signal sequence.

The selection step of the base conversion consists of selection and amplification of fragments which have had ligated to them both a signal sequence and a specific adapter (Figure 2,C). This was conducted using PCR under the following conditions (50 µl): 10 mM KCl, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 20 mM Tris-HCl, 0.1% Triton-X-100, pH 8.8 (Thermopol buffer, New England Biolabs), 2 mM Mg<sup>2+</sup>, 200 µM dNTP (-dCTP) and 200 µM m5-dCTP (Amersham Pharmacia Biotech), 20 pmol adapter1-primer #332 (5'-Biotin-ggctaggtgctgatgaacgcatcg-3'; SEQ ID No 5) and 20 pmol Signal sequence 1-primer #340 (5'-taatacgactcactatagcatgactcgagcctcttcgca-3'; SEQ ID No 5) (MWG-biotech), approx. 3.5 fmol ligated target DNA and 1U Vent polymerase (New England Biolabs). PCR cycling was conducted with a PTC-200 (MJResearch). Hot start: 95°C, 2 minutes, 20 cycles consisting of: 95°C, 15 seconds, 66°C, 20 seconds, 72°C, 30 seconds. Complete extension step: 72°C, 5 minutes. Well 2 in Figure 2 shows the results of the initial cycle of the sequencing method. The correct fragment of 380 bp was generated.

Cycle 2:

In order to convert the next 4 bases, the PCR product was cleaned with the GibcoBRL purification system (Gibco) and then cut with *Sfa*NI and *Eam*1104I. It is possible for this to take place as the signal sequence and the adapter from the initial cycle contain a site for *Eam*1104I and *Sfa*NI respectively. As the sites were located in the primer region, they are not blocked by methylation during PCR. To increase the efficiency of the cutting reaction, the cuts were conducted serially under optimal cutting conditions.

*Sfa*NI cutting: 100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl<sub>2</sub>, 1 mM DTT, pH 7.9 (NEB3, New England Biolabs), 1 µg methylated PCR fragment, 4U *Sfa*NI. Incubation at 37°C for 1 hour. Heat inactivation of the enzyme at 65°C for 10

minutes. A Micro Bio-Spin 6 column (BioRad) was used to clean the fragment. *Eam*1104I cutting: 33 mM Tris-acetate, 10 mM magnesium-acetate, 66 mM potassium-acetate, 0.1 mg/ml BSA, pH 7.9 (Tango Y<sup>+</sup>, Fermentas), *Sfa*NI-digested PCR fragment, 10U *Eam*1104I. Incubated at 37°C for 1 hour, followed by heat inactivating at 65°C for 20 minutes. The digested product was cleaned by using the GibcoBRL purification system (Gibco). The initial step of the conversion was conducted corresponding to the initial cycle, except that a new signal sequence and its associated specific adapter (corresponding to the next 4 bases of the sequence) were added. To reduce potential carry-over problems, signal sequence 2 was designed with an different overhang from signal sequence 1. Ligation conditions: 40 mM Tris-HCl, 10 mM MgCl<sub>2</sub>, 10 mM DTT, 0.5 mM ATP, pH 7.8 (Ligase buffer, Fermentas), 0.5 pmol adapter2 (5'-Biotin-cgacagtacgacggaccagcatcc-3'; SEQ ID No 6 annealed to 5'-acgcggatgctggctcgtcgtactgtcg-3'; SEQ ID No 7) (MWG-biotech), 1 pmol signal sequence 2 (2), 1 Weiss-U T4 DNA ligase (Fermentas). The incubation took place at room temperature (22°C) for 1.5 hours. The ligase was heat-inactivated at 65°C for 10 minutes. PCR amplification took place under the same conditions as the initial cycle, except that a new primer set ( adapter2-primer #347, 5'-Biotin-cgacagtacgacggaccagcatcc-3; SEQ ID No 6' and signal sequence 2-primer #343; 5'-taatacgactcactatagcatcgaatgaccgcctcttcact-3'; SEQ ID No 8). Different primer sets for each sequencing cycle are preferable in order to minimise the danger of amplifying any remains from the previous sequencing cycle. The result of the PCR amplification in the second cycle is shown in Well 3 in Figure 4. The correct fragment of 523 bp was generated. Cycle 3.

Conversion of the next 4 bases and the PCR amplification followed the same pattern as described for Cycle 2: After a serial cutting with *Sfa*NI and *Eam*1104I, the fragment was ligated with signal sequence 3 (3) and adapter3 (5'-Biotin-atcgagcctggcatagcagcatca-3'; SEQ ID No 9 annealed to 5'-aaactgatgctatgccaggctcgat-3; SEQ ID No 10) (MWG-Biotech). The PCR amplification was conducted with the primer set: the adapter3-primer #353 (5'-

atcgagcctggcatagcagcatca-3'; SEQ ID No 9) and signal sequence 3-primer #345 (5'-taatacgactcactatagcaccgggcaggatagactcttcaggt-3'; SEQ ID No 11). The result of the amplification in Cycle 3 is shown in Well 4 in Figure 4. Well 4 shows that two weak and one relatively strong bands are formed. The strong band comes closest to the expected length of 666 bp. The weak bands of the wrong size which can be seen in Well 4 (Cycle 3) and Well 3 (Cycle 2) are most probably the result of carry-over problems and mispriming. The weak band in Well 3 and the weak bands further down in Well 4 correspond to the size of the PCR fragment in the previous cycle. A possible explanation is that incomplete cutting of fragments in one cycle may function as a template in the next PCR cycle. Even though new primer sets in each cycle reduce this problem somewhat, the danger of mispriming is still present because of the enzyme sites the primers have in common. However, this type of mispriming may be eliminated by using more stringent annealing conditions during PCR (e.g.  $Mg^{2+}$ , temperature), the use of more discriminating polymerases, moving the *Eam*1104I site away from 3' on the sequence chain primer, choice of new sequences or immobilisation of the fragments (e.g. the biotin-streptavidin system on microbeads) before cutting so that those fragments entering the next cycle are guaranteed to have been cut. The best solution for other types of mispriming would be to choose new primer sequences and/or optimise PCR conditions. Mispriming events that are caused by the presence of superfluous DNA material (e.g., excess adapters or non-ligated DNA) can be removed by using a strategy of thio-protecting the recessed strand of the adapter. Digestion with a 5'-3' exonuclease (e.g., T7 exonuclease or Lambda exonuclease) prior to PCR will only leave intact one strand of DNA ligated to the adapter. In embodiments where all target sequences are of equal lengths, size selection can be used to remove fragments of incorrect lengths during the process of biochemical conversion.

#### Example 4.

The principle of cyclic conversion where three nucleotides are converted per cycle

The principle of cyclic conversion of nucleic acid bases into readable signal sequence was demonstrated by converting a sequence of 12 bases in a target DNA into its corresponding signal sequence. The conversion took place in steps through a cyclic method, where 3 bases were converted in each cycle for a total number of 4 cycles. The end product was a signal sequence consisting of 12 signal components representing the relevant base sequence in the target DNA. The experiment is described schematically in Figure 5.

A synthetic target DNA fragment of 66 bp, was generated by annealing the following oligonucleotides: # 003 (5'-PHO-  
10 GATCTTGGCTATTTCGTCTCTTGGCTTTTCGTCTGATTGTAGACGCCAACG  
GGACATGATGATGAT-3'; SEQ ID No 12) and # 004 (5'-[PHO-  
CATCATCATCATCATGTCCCGTTGGCGTCTACAATCAGACGAAAAGCCAA  
GAGACGAATAGCCAAG-3'; SEQ ID No 13). As evident from the sequence  
the target molecule contains at the 3' end four consecutive ATG triplets. The  
15 annealed molecule corresponds to the nature of those fragments that are  
obtained after an initial preparation (described in Example 2) in that it has an  
overhang of 3 bases for signal sequence ligation and an overhang of 4 bases  
for ligation to a specific adapter.

The conversion step where the selection marker is attached (Figure 5,  
20 B) was carried out by ligating 1 pmol of the fragment with the specific adapter  
and its associated signal sequence: 50 mM Tris-HCl, 10 mM MgCl<sub>2</sub>, 10 mM  
DTT, 1 mM ATP, 25 µg/ml BSA, pH 7.5 (ligase buffer, New England Biolabs),  
1 pmol adapter # 005 (5'-GATGTAGATGCACTCCCGGACCTC-3'; SEQ ID No  
14 annealed to # 006 5'-GAGGTCCGGGAGTGCATCTA-3'; SEQ ID No 15)  
25 (MWG-biotech), 1 pmol signal sequence # 001 (5'-  
TGTGTCCGCGTGGCTCTTCTGATCTTGGCTTTTCGTCTCTTGGCTATTCTG  
TCT-3'; SEQ ID No 16, annealed to # 002 5'-PHO-  
ATCAGACGAATAGCCAAGAGACGAAAAGCCAAGATCAGAAGAGCCACGC  
GGACACA-3'; SEQ ID No 17) (MWG-biotech), 100 units T4 DNA ligase (New  
30 England Biolabs). The incubation took place at 22 °C in a PTC-200 thermal  
cycler (MJResearch) for 1 hour. Selection and amplification of those  
molecules being successfully ligated to both the adapter and the signal

sequence adapter were conducted using PCR under the following conditions (50µl): 10 mM KCl, 10 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 20 mM Tris-HCl, 0.1% Triton-X-100, pH 8.8 (Thermopol buffer, New England Biolabs), 2 mM Mg<sup>2+</sup>, 200 µM dNTPs (Amersham Bioscience), 10 pmol adapter primer # 006 (5'-GAGGTCCGGGAGTGCATCTA-3'; SEQ ID No 18) (MWG-Biotech) and 10 pmol signal chain primer # 007 (5'-TGTGTCCGCGTGGCTCTTCT-3'; SEQ ID No 19) (MWG-Biotech), approx. 1 pmol ligated target DNA and 0.2 U Vent polymerase (New England Biolabs). PCR cycling was conducted with a PTC-200 (MJResearch). Hot start: 95°C, 2 minutes, 25 cycles consisting of: 95°C, 15 seconds, 59.3°C, 20 seconds, 72°C, 20 seconds. Complete extension step: 72°C, 60 seconds. Well 2 in Figure 6 shows the results of the initial cycle of the sequencing method. The correct fragment of 142 bp was generated.

Cycle 2:

In order to convert the next 3 bases, the PCR product was cleaned using a MinElute PCR clean-up kit (Qiagen) and then cut with Eam1104I and SfaNI. To increase the efficiency of the cutting reaction, the cuts were conducted serially under optimal cutting conditions.

Eam1104I cutting: 33 mM Tris-Acetate, 10 mM magnesium-acetate, 66 mM potassium-acetate, 0.1 mg/ml BSA, pH 7.9 (Tango Y<sup>+</sup>, Fermentas), 0.5 µg PCR fragment, 20 units Eam1104I in a 25µl reaction. Incubated at 37°C for 1 hour. A Micro Bio-Spin 6 column (BioRad) was used to clean the fragment. SfaNI cutting: 100 mM NaCl, 50 mM Tris-HCl, 10 mM MgCl<sub>2</sub>, 1 mM DTT, pH 7.9 (NEB3, New England Biolabs), 0.5 µg PCR fragment, 2.5 units SfaNI. Incubation at 37°C, for 15 minutes in a 50µl reaction.

The digested product was cleaned by PAGE (PolyAcrylamide Gel Electrophoresis) and purified from the gel using a crush and soak method. Gel particles were removed using a Micro Bio-Spin 6 column and the DNA purified using a MinElute Reaction clean-up column (Qiagen).

The conversion step was conducted corresponding to the initial cycle using the same signal sequence and its associated specific adapter. The rest of the procedure followed the same pattern as described for cycle 1 except that an agarose gel and a gel purification kit (QiaexII, Qiagen) was used to



purify the sample after digestion. The result of the PCR amplification in the second cycle is shown in Well 3 in Figure 6. The correct fragment of 172 bp was generated.

- Cycle 3 and 4 followed the same pattern as described for cycle 2. The
- 5 result of the PCR amplification is shown in Wells 4 and 5 where the correct fragments of 202 bp and 232 bp were generated.

**CLAIMS**

1. A method for identifying specific characteristics of target polynucleotides present in a sample, comprising the steps of:
  - 5 i) attaching to one end of each target polynucleotide in the sample a polynucleotide signal sequence that is specific for the characteristic under study;
  - ii) contacting the target polynucleotides with a molecule that interacts with the target polynucleotide if the characteristic is present;
  - 10 iii) separating those target polynucleotides that interact from those that do not;
  - iv) optionally repeating steps (i) to (iii); and
  - v) identifying which signal sequences are present on the separated target polynucleotides, and in which order, to thereby determine  
15 the characteristics of each target polynucleotide.
2. A method according to claim 1, wherein step (iii) is carried out by
  - (a) attaching a polynucleotide adapter sequence to those target polynucleotides that interact with the molecule; and
  - (b) carrying out a polynucleotide amplification reaction on those target  
20 polynucleotides that comprise both the signal sequence and adapter.
3. A method according to claim 1 or claim 2, wherein the method is carried out to determine the nucleic acid sequence of the target polynucleotides.
4. A method according to claim 2, wherein the adapter polynucleotide comprises a restriction enzyme recognition sequence that permits later  
25 cleavage after the amplification step.
5. A method according to claim 2, wherein amplification is carried out using the polymerase reaction.
6. A method according to claim 5, wherein the adapter and signal sequence comprise recognition sites for oligonucleotide primers used in the  
30 polymerase reaction.
7. A method according to any preceding claim, wherein the sample is separated into n reaction compartments, where n is the number of different

characteristics under study, and the signal sequence for each compartment is specific for that compartment.

8. A method according to claim 4, wherein the restriction enzyme recognition sequence is specific for a class IIs enzyme.

5 9. A method according to claim 8, wherein the enzyme is SfaNI or Earl.

10. A method according to claim 5, wherein the polymerase reaction is carried out using methyl-dCTP as a replacement for dCTP.

11. A method according to claim 2, wherein the adapter is immobilised on a support material.

10 12. A method according to claim 6, wherein sequential signal sequences and optionally sequential adapters comprise recognition sites for different oligonucleotide primers.

13. A method for determining the sequence of a target polynucleotide, comprising the steps of:

15 i) treating a sample of a double-stranded target polynucleotide to create overhangs at each end, one of which is to be sequenced, each overhang having a defined number of bases;

ii) dividing the sample and contacting each separate sample with a double-stranded polynucleotide signal sequence and a double stranded adapter polynucleotide, each signal sequence  
20 representing a specific polynucleotide sequence of the same length as that of the overhang to be sequenced and comprising an overhang that permits hybridisation and ligation to the end of the target polynucleotide opposite that being sequenced, and  
25 each adapter comprising an overhang that is of complementary sequence to the overhang sequence being sequenced;

iii) carrying out the polymerase reaction on the sample(s) using primers that hybridise at the ends of the signal sequence and adapter sequence, wherein the product of the polymerase  
30 reaction comprises a restriction site that permits cleavage of the adapter to form a new overhang to be sequenced optionally repeating steps (i) to (iii) using restriction enzymes to create the

overhangs; and

- iv) identifying which signal sequences are present on the amplified products, and in which order, to thereby determine the sequence of the target polynucleotide.

- 5 14. A method according to claim 13, wherein the overhang that ligates to the signal sequence is at least 3 bases.
15. A method according to claim 13 or claim 14, wherein the overhang to be sequenced is 4 bases.




Figure 1

2/6




Figure 2

3/6





Figure 3

4/6

- 1) DNA-ladder (LowRange, Fermentas)
- 2) One cycle (66°C)
- 3) Two cycles (66°C)
- 4) Three cycles (66°C)
- 5) One cycle (70°C)
- 6) Two cycles (70°C)
- 7) Three cycles (70°C)
- 8) – template (negative control)

1000  
900  
800  
700  
600  
500  
400  
300




Annealing 66°C    Annealing 70°C

One cycle (4 bp)

Two cycles (8 bp)

Three cycles (12 bp)



380 bp

523 bp

666 bp

Figure 4



5/6




Figure 5

6/6




Figure 6

## INTERNATIONAL SEARCH REPORT

International Application No

P/GB2004/001673

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 00/39333 A (JONES ELIZABETH LOUISE ; LEXOW PREBEN (NO)) 6 July 2000 (2000-07-06) page 9 pages 33-34	1, 3
Y	page 21; examples 1, 14 page 97	2, 4-15
X	WO 01/61036 A (TOWLER PHILIP DEAN ; LEXOW PREBEN (NO); COMPLETE GENOMICS AS (NO)) 23 August 2001 (2001-08-23) examples 2, 13	1-5, 7, 8, 11
Y		6, 9, 10, 12-15
X	US 5 714 330 A (BRENNER SYDNEY ET AL) 3 February 1998 (1998-02-03) the whole document	1, 3, 7
Y		2, 4-6, 8-15
	-/-	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

3 September 2004

Date of mailing of the international search report

13/09/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Reuter, U

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB2004/001673

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 701 001 A (HITACHI LTD) 13 March 1996 (1996-03-13) columns 9-10; figure 1 -----	1,3,7
X	US 6 258 533 B1 (JONES DOUGLAS H) 10 July 2001 (2001-07-10)	1,2
Y	columns 31-32; figure 4 columns 24-25 column 12 -----	4-15
A	US 6 258 539 B1 (HUNKAPILLER MICHAEL W ET AL) 10 July 2001 (2001-07-10) the whole document -----	1-15
A	WO 00/60124 A (UNIV YALE) 12 October 2000 (2000-10-12) the whole document -----	1-15

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

T/GB2004/001673

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0039333	A	06-07-2000	NO 20013130 A	23-08-2001
			AU 774389 B2	24-06-2004
			AU 1881000 A	31-07-2000
			CA 2354635 A1	06-07-2000
			CN 1334879 T	06-02-2002
			EE 200100340 A	15-10-2002
			EP 1141399 A1	10-10-2001
			WO 0039333 A1	06-07-2000
			JP 2003503007 T	28-01-2003
			NO 996425 A	26-06-2000
			US 2004076998 A1	22-04-2004
			US 2002028458 A1	07-03-2002
WO 0161036	A	23-08-2001	AU 3214001 A	27-08-2001
			WO 0161036 A2	23-08-2001
US 5714330	A	03-02-1998	US 5599675 A	04-02-1997
			US 5552278 A	03-09-1996
			US 5856093 A	05-01-1999
			US 5831065 A	03-11-1998
			AT 201238 T	15-06-2001
			AU 685628 B2	22-01-1998
			AU 2379195 A	23-10-1995
			CA 2163662 A1	12-10-1995
			DE 69520917 D1	21-06-2001
			DE 69520917 T2	20-12-2001
			DK 703991 T3	18-06-2001
			EP 0703991 A1	03-04-1996
			ES 2159635 T3	16-10-2001
			GR 3036314 T3	31-10-2001
			JP 8511174 T	26-11-1996
			PT 703991 T	30-10-2001
			WO 9527080 A2	12-10-1995
EP 0701001	A	13-03-1996	JP 8070898 A	19-03-1996
			CN 1127887 A	31-07-1996
			EP 0701001 A2	13-03-1996
US 6258533	B1	10-07-2001	US 5858671 A	12-01-1999
			AU 3069599 A	20-09-1999
			WO 9945153 A2	10-09-1999
			US 2003175780 A1	18-09-2003
			US 2003044784 A1	06-03-2003
			US 6190889 B1	20-02-2001
			US 2002072055 A1	13-06-2002
US 6258539	B1	10-07-2001	US 6232067 B1	15-05-2001
			AU 5560199 A	06-03-2000
			WO 0009756 A1	24-02-2000
WO 0060124	A	12-10-2000	AU 4211500 A	23-10-2000
			CA 2367400 A1	12-10-2000
			EP 1190092 A2	27-03-2002
			JP 2002540802 T	03-12-2002
			WO 0060124 A2	12-10-2000
			US 6261782 B1	17-07-2001
			US 2002106649 A1	08-08-2002